No Data
No Data
J.P. Morgan Maintains Health Catalyst(HCAT.US) With Buy Rating, Raises Target Price to $13
CCORF Maintains Health Catalyst(HCAT.US) With Buy Rating, Maintains Target Price $11
Buy Rating Affirmed on Health Catalyst Amid Positive Growth and Strategic Initiatives
Health Catalyst to Participate in Upcoming Investor Conferences
Express News | Wishin Expands Relationship With Health Catalyst, Signing Multi-Year Partnership to Migrate to Ninja Universe™ Suite
WISHIN Expands Relationship With Health Catalyst, Signing Multi-Year Partnership to Migrate to Ninja Universe Suite
No Data
No Data